MARKETVUE® REPORT: Frontal Fibrosing Alopecia burden of disease is significant with half of patients unable to achieve complete response to treatment
According to REACH Market Research, dermatologists agree that Frontal Fibrosing Alopecia (FFA) is generally more difficult to treat, and less likely to have an optimal response to treatment than Alopecia Areata [...]
MARKETVUE® REPORT: Over 80% of U.S. gastroenterologists have prescribed Dupixent for Eosinophilic Esophagitis since its 2022 approval
First-to-market Regeneron/Sanofi's Dupixent (dupilumab) sees strong uptake in Eosinophilic Esophagitis (EoE) since its May 2022 FDA approval, according to findings from REACH Market Research. NEWTON, Mass., Feb. 21, 2023 /PRNewswire/ -- Despite being recognized [...]
5 Solutions to Overcome Challenges Conducting Rare Disease Epidemiology
Epidemiology and patient population dynamics are at the core of understanding any disease market. For rare diseases, getting a firm grasp of the disease prevalence and incidence, diagnosis rates, treatment rates, representation of clinically [...]
3 Key Insights for Rare Disease Drug Developers: GSD Type 1a
Rare disease market research that captures the voice of the patient is indispensable for understanding a rare disease market. Moreover, because treatment planning for rare diseases is often a process [...]
MARKETVUE® REPORT: Frontal Fibrosing Alopecia burden of disease is significant with half of patients unable to achieve complete response to treatment
According to REACH Market Research, dermatologists agree that Frontal Fibrosing Alopecia (FFA) is generally more difficult to treat, and less likely to have an optimal response to treatment than Alopecia Areata [...]
MARKETVUE® REPORT: Over 80% of U.S. gastroenterologists have prescribed Dupixent for Eosinophilic Esophagitis since its 2022 approval
First-to-market Regeneron/Sanofi's Dupixent (dupilumab) sees strong uptake in Eosinophilic Esophagitis (EoE) since its May 2022 FDA approval, according to findings from REACH Market Research. NEWTON, Mass., Feb. 21, 2023 /PRNewswire/ -- Despite being recognized [...]
5 Solutions to Overcome Challenges Conducting Rare Disease Epidemiology
Epidemiology and patient population dynamics are at the core of understanding any disease market. For rare diseases, getting a firm grasp of the disease prevalence and incidence, diagnosis rates, treatment rates, representation of clinically [...]
3 Key Insights for Rare Disease Drug Developers: GSD Type 1a
Rare disease market research that captures the voice of the patient is indispensable for understanding a rare disease market. Moreover, because treatment planning for rare diseases is often a process [...]